What Is GIP?

Introduction

GIP, short for Glucose-Dependent Insulinotropic Polypeptide, is a naturally occurring hormone released by the small intestine after you eat.

It belongs to a group of hormones known as incretins, which help the body respond to food by regulating insulin, blood sugar and digestion.

GIP has received much more attention in recent years because newer medications such as Tirzepatide target both GIP and GLP-1 receptors.

What Does GIP Do?

After you eat, nutrients entering the small intestine trigger the release of GIP.

One of its main roles is to help the pancreas release insulin when blood sugar levels rise. Insulin then helps move glucose from the bloodstream into the body’s cells, where it can be used for energy.

GIP may also influence appetite, fat storage and the way the body manages energy.

💡 Key Point: GIP helps the body respond to food by supporting insulin release and blood sugar control.

What Is an Incretin Hormone?

Incretins are hormones released by the digestive system after eating.

Their job is to help the body prepare for and manage the nutrients entering the bloodstream.

GIP and GLP-1 are the two main incretin hormones. Both help regulate insulin, but they have different effects throughout the body.

💡 Key Point: GIP and GLP-1 are both incretin hormones released in response to food.

How Is GIP Different from GLP-1?

GIP and GLP-1 both support insulin release when blood sugar rises, but they do not work in exactly the same way.

GLP-1 is strongly associated with:

Reduced appetite
Increased fullness
Slower stomach emptying
Improved blood sugar regulation

GIP is more closely associated with:

Insulin release after meals
Nutrient processing
Energy balance
Fat metabolism

Researchers are still studying exactly how GIP affects appetite and body weight when used alongside GLP-1 receptor activation.

💡 Key Point: GIP and GLP-1 have overlapping roles, but each affects metabolism differently.

Why Is GIP Important for Weight Loss?

GIP was not always viewed as an obvious target for weight management.

However, research into dual-agonist medications has shown that activating both GIP and GLP-1 receptors can produce powerful effects on appetite, blood sugar and body weight.

Scientists believe GIP may help enhance or complement the appetite-regulating effects of GLP-1 when the two pathways are activated together.

This combined approach is used by Tirzepatide.

💡 Key Point: GIP appears to work particularly well when combined with GLP-1 receptor activation.

Which Medications Target GIP?

Not every medication in this category targets the GIP receptor.

Semaglutide targets GLP-1.

Tirzepatide targets GLP-1 and GIP.

Retatrutide targets GLP-1, GIP and glucagon.

This is why Tirzepatide is called a dual agonist, while Retatrutide is called a triple agonist.

💡 Key Point: GIP receptor activation is one of the main differences between Semaglutide and newer medications such as Tirzepatide.

Does GIP Directly Burn Fat?

GIP should not be thought of as a simple fat-burning hormone.

Its role is more complex and includes insulin release, nutrient storage, energy regulation and communication between the digestive system and other organs.

When GIP is targeted alongside GLP-1, the combined effects may help reduce food intake and support weight loss.

However, body fat is still lost because a person maintains an energy deficit over time.

💡 Key Point: GIP does not independently melt body fat—it forms part of a wider system controlling appetite and metabolism.

Key Takeaways

GIP stands for Glucose-Dependent Insulinotropic Polypeptide.
It is released by the small intestine after eating.
It helps the pancreas release insulin when blood sugar rises.
GIP and GLP-1 are the body’s two main incretin hormones.
Tirzepatide targets both GLP-1 and GIP.
Retatrutide targets GIP alongside GLP-1 and glucagon.
GIP may strengthen the effects of GLP-1 when both pathways are activated together.

💡 Remember: GIP is one part of a much larger system controlling blood sugar, appetite and energy balance.